Prefilled Syringes Market Size, Trends and Growth Analysis by Material (Glass Syringes, Oil Siliconized Syringes, Baked on Silicone Syringes and Plastic Syringes), Type (Conventional Prefilled Syringes and Safety Prefilled Syringes), Design (Single-Chamber Prefilled Syringes, Dual-Chamber Prefilled Syringes and Customized Prefilled Syringes), End User (Hospitals/Clinics and Ambulatory Surgical Center) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2032

Global Prefilled Syringes Market Overview

The Prefilled Syringes Market Size was valued at USD 6.39 billion in 2022 and is projected to grow from USD 6.98 Billion in 2023 to USD 15.59 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.45% during the forecast period (2023 - 2032). The Demand for self-injection and associated technologies are in greater Demand, and Increasing prevalence, incidence, and number of different chronic illnesses. These are just a few of the market drivers that are driving the market.

Source Secondary and Primary Research, MRFR Database and Analyst Review

Biologics and biosimilars are quickly replacing Drugs based on chemicals in the global life science market. Biologics are excellent for focused distribution and inclination boosting since they are less prone to combine with other medications. The primary reasons driving the market expansion are an increase in the demand for effective and user-friendly drug delivery systems and an increase in the efforts made by healthcare professionals to lower hospital errors. During the projected period, the market expansion is anticipated to be driven by the rapid development of feature-rich devices with underlying technology breakthroughs enabling safer and more convenient self-injections for patients. Due to the rise in biologics used to treat chronic illnesses, producers of medicines and packaging are under pressure to create more sophisticated systems of drug delivery and container closing.

As a result, these syringes are now widely used for the safe delivery of biologics and biosimilars. A considerable increase in the production of biological medicines is predicted to support business growth. The manufacturer has affixed a needle to a single-dose immunization packet in a prefilled syringe. Historically, syringes were made of metal or glass, but in recent years, plastic and disposable syringes have been used to shield the needle and prevent its reuse. As a result, prefilled syringes are more in demand than conventional glass vials for packaging prescription pharmaceuticals in the healthcare sector.

Another potential admixture-related contamination risk exists when a syringe is inserted into a drug container to draw out a dose. By using prefilled syringes, the risk of medication contamination is reduced. Pre-sterilized syringes increase safety by eliminating this risk and eliminating the need for additional on-site vial cleansing and depyrogenation procedures. Biomedical treatments and therapeutic vaccinations are fast displacing traditional treatment options due to their increased efficacy, patient safety, and fewer adverse effects. To maintain the potency of these incredibly fragile medicines, inventive packaging solutions are now more important than ever. Therefore, prefilled syringes are an ideal choice for storing these medications. Additionally, the growth of the biological medicine industry has directly helped the demand for prefilled syringes.

In Mounjaro, medication pre-filling in an injection pen, Lilly opened a new tab after being given the green light in January 2024 and announced it would take only weeks to get the dosage for British patients. Mounjaro is known to combat diabetes and obesity. A US pharmaceutical company indicated that Medicines & Healthcare Products Regulatory Agency (MHRA) approval made Britain the first major market where the drug could be used in a convenient multi-shot pen referred to as Kwikpen.

In April 2023, Mounjaro subcutaneous injectable 2.5 mg/ 5 mg ATEOS was launched in Japan by Mitsubishi Tanabe Pharma Corporation (MTPC) and Eli Lilly Japan. Once a week, the medicine is injected under your skin using a single-use autoinjector device (ATEOS). Pressing an injection button of a particular pen injector loads needle with medicine once, which inserts beneath the patient’s skin automatically. There is no need for the patient to apply medication or handle needle.

In February 2023, Phillips-Medisize increased its product line to include a disposable pen injector, which is a subsidiary of Molex company. The firm introduced this new addition of disposable pen injectors into its business products. Phillips-Medisize supplies pharma firms with an environmentally competitive pen injector suitable for highly productive manufacturing and accelerates them through the market at lower costs.

Sanofi’s SoloSmart can be attached to either SoloStar or DoubleStar insulin injection pens in February 2023. It shows when drugs have been administered together with quantities injected per time period. This collaboration has enabled Glooko app users to visualize their data, making it easier for Sanofi to track this information on behalf of clients within their mobile devices while they are away from home.

AstraZeneca and Amgen’s Tezspire (tezepelumab) pre-filled pen was approved by U.S Food and Drug Administration (FDA) in the United States on a pre-filled basis in February 2023. Tezspire pre-filled pen is used for self-administration in patients aged 12 years and older with severe asthma. Therefore, launching the new injection pen device could be vital as it will create a strong presence for the company, among others existing within this industry.

Prefilled Syringes Market Trends

• Rising Demand for biologics and biosimilars and advancements in prefilled biologic drug products will boost market growth

Biologics and biosimilars rapidly replace chemical-based medications in the worldwide life science market. Because they are less likely to interact with other drugs, biologics are great for targeted delivery and boost inclination. Manufacturers of pharmaceuticals and packaging are under pressure to develop more advanced container closure and drug delivery methods due to the increase in biologics used to treat chronic illnesses. As a result, the adoption of these syringes for the secure administration of biologics and biosimilars has significantly increased. For instance, 98 biosimilars have received approval in India, according to the Central Drugs Standard Control Organization (CDSCO).

The expansion of the worldwide prefilled syringes market is anticipated to be driven by the rising demand for biological medications and expanding advances in injectable delivery systems. Leading players have taken an interest in biological medications since they focus on disorders for which no effective treatments exist. For instance, F. Hoffmann-La Roche Ltd. declared in April 2021 that the U.S. Food and Drug Administration had approved its additional biologics application for the prefilled syringe of Xolair (omalizumab) designed for self-injection. IgE blockers like Xolair are used for chronic idiopathic urticaria, asthma, and nasal polyps. Similar to this, Glenmark Pharmaceuticals Ltd. reported in May 2021 that Icatibant injection, a generic version of Firazyr injection, has received approval from the U.S. Food and Drug Administration. It is offered as a single-dose prefilled syringe in a 30 mg/3 mL (10 mg/mL) dosage. Thus, this factor is driving the market CAGR.

The need for biological medications is also projected to rise as autoimmune disorders, cancer, and other non-communicable illnesses rise. For instance, the International Agency for Research on Cancer (IARC) predicts that by 2040, there will be 27.5 million additional instances of cancer worldwide. The American Autoimmune Related Diseases Association Inc. (AARDA) also estimates that 50 million Americans today have autoimmune illnesses. Future projections indicate that this number will increase, raising Demand for biologics in the United States.

Self-Injecting Parenteral Device Adoption is Growing, Driving Market Growth The current method of administering parenteral medications is using prefilled injections as a self-injecting device. These are practical and make administration easier. While drawing pharmaceuticals from the drug vials, these items enhance patient safety and reduce exposure to dangerous substances. As a result, self-injecting devices have several benefits for the user, including fewer dosing mistakes and enhanced patient safety due to their pre-measured dose. Therefore, the above factors help increase the use of and preference for this product among medical professionals and patients, which is positive for expanding the worldwide market. Thus, it is anticipated that this aspect will accelerate Prefilled Syringes market revenue globally.

Prefilled Syringes Market Segment Insights

Prefilled Syringes Material Insights

Based on Material, the market segments of Prefilled Syringes includes Glass Syringes, Oil Siliconized Syringes, Baked Silicone Syringes and Plastic Syringes. The glass syringes segment held the majority share in 2022 in the  Prefilled Syringes market data. The current industry standard for prefilled syringes is glass syringes. Glass syringes are straightforward, and medical professionals may inspect them for particle contamination. Because of its transparency and inertness, which ensure the dosage's purity, Glass is a dependable option. However, it is anticipated that growing consumer demand for safer products that enable self-administration of medicine and increased glass fragility during transportation would restrict the use of glass syringes in the  market for prefilled syringes.

Prefilled Syringes Type Insights

Based on Type, the  Prefilled Syringes market segmentation includes Conventional Prefilled Syringes and Safety Prefilled Syringes. The Safety Prefilled Syringes segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The burden on hospitals is lessened partly by the growing elderly population worldwide, the development of biological medicines for people with chronic diseases and the outsourcing of low-risk medical operations for chronic patients.

Figure 2 Prefilled Syringes Market, by Type, 2022 & 2030 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Prefilled Syringes Design Insights

Based on Design, the Prefilled Syringes market data includes Single-Chamber Prefilled Syringes, Dual-Chamber Prefilled Syringes and Customized Prefilled Syringes. The Single-Chamber Prefilled Syringes segment dominated the market revenue of Prefilled Syringes in 2022 and is projected to be the faster-growing segment during the forecast period 2022-2030. Using single-chamber prefilled syringes over vials has several benefits, including optimal API usage with less overfill, decreased material requirements, less drug waste in clinical studies, and ease of storage and disposal. In addition, the use of self-administered parenteral medications is growing due to the frequency of chronic illnesses and the advantages that prefilled syringes provide.

Prefilled Syringes End-user Insights

Based on End-user, the market data of Prefilled Syringes includes Hospitals/Clinics and Ambulatory Surgical Centers. The Hospitals/Clinics segment dominated the Prefilled Syringes market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Due to an increase in the number of patients admitted with cancer, diabetes, and cardiovascular disorders. Due to their numerous uses, hospitals are the main consumers of these syringes. The market is also anticipated to rise due to increased attention paid to developing healthcare infrastructure in emerging nations in Asia, the Pacific, and Africa. This segment's growth is predicted to be negatively impacted by the rising trend of self-care and the availability of gadgets that allow fewer visits to healthcare providers.

News:

The only 100 mcg per 2 mL presentation offered on the market in a manufacturer-prepared prefilled syringe, Fresenius Kabi announced the launch and immediate availability of Fentanyl Citrate Injection, USP in 100 mcg per 2 mL Simplist® ready-to-administer prefilled syringes in the United States. The most recent manufacturer-prepared product in the business's exclusive, ready-to-use Simplist prefilled syringe portfolio is Fresenius Kabi Fentanyl Citrate Injection, USP. These syringes are made for effective medication delivery and ease of use, helping to reduce steps where mistakes can happen.1 In its Simplist portfolio, Fresenius Kabi offers 14 products in 25 presentations. The FDA in the United States has a shortage alert for fentanyl citrate right now.

Prefilled Syringes Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. Europe's Prefilled Syringes market accounted for USD 10.21 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. Due to reasons including the healthcare professionals' strong preference for prefilled injectable devices to reduce needle-related injuries. Major market companies, including Gerresheimer AG, SCHOTT group, Stevanato Group, Haselmeier AG, and Owen Mumford Ltd., are also in the area. Over time, several businesses have increased their local presence. Moreover, the U.K. market of Prefilled Syringes held the largest market share, and the Germany market of Prefilled Syringes was the fastest-growing market in the region.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3 PREFILLED SYRINGES MARKET SHARE BY REGION 2022 (%)

Source Secondary and Primary Research, MRFR Database and Analyst Review

Due to the increase in various chronic conditions, including diabetes and rheumatoid arthritis, which is projected to increase the need for extended medication administration at an exact dosage, North America is predicted to have the second-largest market share. The proliferation of major companies with robust distribution networks and an increase in product releases are expected to fuel market expansion in North America.

With the emergence of quickly expanding economies and the availability of a sizable untapped market, Asia Pacific Prefilled Syringes market is anticipated to see the quickest CAGR between 2022 and 2030. The region's market is anticipated to increase due to favorable demographic variables, including the huge population and rising incidence of chronic illnesses. The market for developed prefilled syringes is made up of nations like China. Ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and type 2 diabetes are the most prevalent chronic NCDs in China among persons aged 60, according to Front Public Health in 2020. Further, the China market of Prefilled Syringes held the largest market share, and the India market of Prefilled Syringes was the fastest-growing market in the region.

Prefilled Syringes Key Market Players & Competitive Insights

Major industry companies are investing a lot of money in R&D to expand their product offerings, which will spur further market expansion for coffee. With significant industry changes, including new product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their presence. To grow and remain in a market that is becoming more and more competitive, Prefilled Syringes industry competitors must provide affordable products.

Manufacturing locally to cut operational costs is one of the main business methods producers use in the Prefilled Syringes industry to benefit customers and increase the market sector. The Prefilled Syringes industry has recently given medicine some of the most important advantages. The market of Prefilled Syringes major player such as Nestle, JM Smucker Company, The Kraft Heinz Company and Starbucks Prefilled Syringes Company.

German multinational glass manufacturer Schott AG specializes in the production of Glass. In August 2021, SCHOTT AG, a German specialty glass company, acquired 50% ownership in the SCHOTT Kaisha joint venture in India with its most recent partner Serum Institute of India. With the purchase, Serum secured its supply of premium pharmaceutical packaging in the face of rising Demand.

The American multinational medical technology business Becton, Dickinson and Company, better known as B.D., produces and markets reagents, instrument systems, and medical devices. In some regions, B.D. also offers consulting and analytics services. B.D. announced intentions to split its Diabetes Care segment into a distinct, publicly listed company in May 2021. ("NewCo"). B.D. has greatly aided the development of insulin syringes and other items. Diabetes Care supports around 30 million patients and produces about 8 billion injectable devices annually.

Key Companies in the market of Prefilled Syringes include

• Medtronic, 


• OMPI (A Stevanato Group Company) ¸


• Terumo Corporation, 


• Abbott¸ 


• Nipro Corporation, 


• Vetter Pharma International GmbH, 


• Gerresheimer AG, 


• Schott AG, 


• Baxter, 


• Becton, Dickinson and Company, 


• West Pharmaceutical, 


• Weigao Group, 


• and others.

Prefilled Syringes Industry Developments

October 2020 SCHOTT AG and Credence MedSystems have joined forces to employ TOPPAC, a polymer syringe, and Syria, a pre-fillable glass system, combined with Credence Companion technology. The two businesses will probably work together to integrate the technology and give the pharmaceutical industry a special and innovative approach to administering injectable medications utilizing prefilled syringes.

April 2021 Nipro Pharma Packaging International announced that the Nipro D2F pre-fillable syringes are compatible with Schreiner MediPharm Needle-Trap, expanding the range of products offered (safety system).

October 2021 In collaboration with Aptar Pharma, Becton, Dickinson and Company introduced the BD SCF PremiumCoat Plunger Stopperade to enable the injection of biologics using prefilled syringes.

In August 2023, Becton Dickinson expanded its collaboration with Bill & Melinda Gates Foundation, Children’s Investment Fund Foundation (CIFF) and Pfizer to deliver over 320 million doses of Sayana® Press injectable contraceptive developed by Pfizer which is administered through BD’s Uniject™ Auto-Disable Prefillable Injection System via to the year 2030.

Prefilled Syringes Market Segmentation

Prefilled Syringes Material Outlook (USD Million, 2018-2030)

• Glass syringes


• Oil Siliconized Syringes


• Baked on silicone syringes


• Plastic Syringes

Prefilled Syringes Type Outlook (USD Million, 2018-2030)

• Conventional Prefilled Syringes


• Safety Prefilled Syringes

Prefilled Syringes Design Outlook (USD Million, 2018-2030)

• Single-Chamber Prefilled Syringes


• Dual-Chamber Prefilled Syringes


• Customized Prefilled Syringes

Prefilled Syringes End-User Outlook (USD Million, 2018-2030)

• Hospitals & Clinics


• Ambulatory Surgical Center

Prefilled Syringes Regional Outlook (USD Billion, 2018-2030)

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America